NASI North American Scientific (MM)

North American Scientific, Inc. (Nasdaq:NASI) today announced the renewal by Premier Inc. of a new three year contract to supply its member hospitals with Prospera� I-125 and Pd-103 brachytherapy sources. Premier Inc. is one of the largest healthcare group purchasing organizations in the United States. The new three-year contract, which will become effective on August 1, 2007, will be implemented seamlessly upon the expiration of the current contract. �We are proud that Premier has chosen to renew our brachytherapy seed contract and we look forward to continuing our service to their member hospitals,� stated John Rush, President and Chief Executive Officer of North American Scientific, Inc. �The renewal of the Premier contract marks another important milestone in the continued market acceptance of the Prospera� brand in the brachytherapy market, and we look forward to strengthening our collaboration with Premier as we work together in the battle against prostate cancer.� About North American Scientific North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera� brachytherapy seeds and SurTRAK� needles and strands used primarily in the treatment of prostate cancer. In addition the Company plans to commercialize its ClearPath� multi-channel catheter breast brachytherapy devices in 2007, which are the only devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. North American Scientific�s NOMOS� Radiation Oncology Division provides external beam radiation therapy products for Serial Tomotherapy Intensity Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT). Serial tomotherapy IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. These products are marketed under the trade names nomosSTAT�and CORVUS� (our proprietary treatment planning software). The Company's IGRT products, BAT�, BATCAM� and nTRAK�, provide fast and accurate targeting and localization of a treatment volume on a daily basis. More than 500 hospitals and research sites worldwide are equipped with the Company's clinically proven serial tomotherapy, inverse treatment planning, image-guidance and ancillary treatment solutions. Please visit www.nasmedical.com for more information. About Premier, 2006 Malcolm Baldrige National Quality Award recipient Serving 1,700 hospitals and more than 46,500 other healthcare sites, Premier is the largest healthcare alliance in the United States dedicated to improving patient outcomes while safely reducing the cost of care. Owned by not-for-profit hospitals, Premier operates the nation's largest healthcare purchasing network, the most comprehensive repository of hospital clinical and financial information and one of the largest policy-holder owned, hospital professional liability risk-retention groups in healthcare. Headquartered in San Diego, Premier has offices in Charlotte, N.C. and Washington. For more information, visit www.premierinc.com.